A Multiple Ascending Dose, Phase 1, Double-Blind, Study to Investigate the Safety and Pharmacokinetics of NTRX-07 in Healthy Volunteers and Patients With Early Alzheimer's Disease (AD), With an Exploratory Fed-Fasted Assessment
Latest Information Update: 09 Jan 2024
At a glance
- Drugs NTRX 07 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors NeuroTherapia
- 24 Oct 2023 According to a NeuroTherapia media release, overall positive safety results from this study supports advancement into Phase 2 clinical study.
- 24 Oct 2023 According to a NeuroTherapia media release, results from this study was presented at the Clinical Trials on Alzheimers Disease (CTAD) conference, taking place in Boston, Mass., Oct. 24-27, 2023.
- 24 Oct 2023 Results (n=32) presented in a NeuroTherapia media release.